Shopping Cart
- Remove All
Your shopping cart is currently empty
Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $413 | In Stock | |
| 5 mg | $1,230 | In Stock | |
| 10 mg | $1,990 | In Stock | |
| 25 mg | $2,950 | In Stock | |
| 50 mg | $3,980 | In Stock |
| Description | Tidutamab (XmAb-18087) is a humanized bispecific antibody targeting the growth inhibitory receptor 2 (SSTR2) and T-cell binding domain (CD3) with antitumor activity for the study of gastric neurosecretory tumors. |
| Targets&IC50 | SSTR2+ CHO cells (human):2.2 μg/mL (ED50) |
| In vitro | Tidutamab was able to bind to human SSTR2+ CHO cells in the concentration range of 0-100,000 ng/mL with an ED50 value of 2.2 μg/mL and mediated the killing of SSTR2+ target cells by T cells. [1] |
| In vivo | In NSG mice, Tidutamab was able to stimulate killing of SSTR2+ A549 lung cancer tumors by human T cells after a single intraperitoneal injection at a dose of 3 mg/kg. [1] |
| Synonyms | XmAb-18087, XmAb18087 |
| Cas No. | 2148354-90-7 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.